Developing a novel EEG-based index for evaluating amyloid and TAU burden in alzheimer's disease
Ended Project Grant Awarded Last action
- Award ID
- R44AG080940
- Recipient
-
Spark Neuro Inc. UEI GW3LFLL3NWT3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,295,007
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- New York, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alzheimer's disease (ad) is a progressive, neurodegenerative condition that impacts 44 million people globally. IT is the most common cause of dementia-accounting for 80% of all dementia diagnoses-and predominantly affects older people. To date, ad has no cure. Thus, IT is imperative to diagnose patients as early as possible to maximize the efficacy of symptom management strategies. However, existing ad diagnostic and monitoring options remain subpar, leaving urgent need for sensitive, reliable, and convenient methods to measure ad. New research suggests that electroencephalography (EEG) -based biomarkers can assess neural degeneration caused by ad long before tissue loss or behavioral symptoms appear. Spark neuro aims to unlock the full potential of EEG through a novel software platform: spark scan. Combining EEG with the capabilities of machine learning, spark scan better assesses cognitive health and neurodegeneration, aiding the diagnosis of ad. In the proposed direct-to-phase II sbir project, the company will enhance the existing spark platform by developing a novel alzheimer's disease pathology index that tracks patient amyloid and TAU burden. Developed with CSF data collected from johns hopkins university, the pathology index will be a continuous score that corresponds to a patient's pathological disease burden. After updating the software, the spark team will employ human factors testing to enhance the usability and utility of the updated platform and clinical report before submitting findings for FDA DE novo approval. This work will progress the spark platform by providing a granular measure of ad-related pathology, extending beyond current capabilities.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,175,044 | |
| Amendment | $1,175,044 | |
| Amendment | $1,314,973 | |
| Amendment | $1,314,973 | |
| Original award | $1,314,973 |
Quick answers
Who received award R44AG080940?
R44AG080940 was awarded to Spark Neuro Inc. by National Institute on Aging (National Institutes of Health) on February 1, 2023.
How much is award R44AG080940 worth?
$6,295,007 has been obligated on R44AG080940.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award